Longevity Report · Week of July 18, 2026
Hype meets hard data: rapamycin, strength doses, biomarkers, sleep thresholds, and reversing aging damage
- First Rapamycin-Plus-Exercise Trial Disappoints as Field Confronts Its Evidence GapHere are two facts most readers hold at the same time without noticing they cancel out.
- Peter Attia Challenges Metformin's Geroprotector Reputation Amid TAME-Era EnthusiasmStart with the claim, because it should have stopped everyone cold: people with type 2 diabetes, taking metformin, outlived people who did not have diabetes at all.
- Harvard 30-Year Study Pins Strength-Training Longevity Sweet Spot at 90-120 Minutes WeeklyNinety to 119 minutes a week. That is the number, and above 120 minutes it stops mattering. In a cohort of 147,374 adults tracked for up to three decades, the mortality curve for strength training flattened at roughly tw…
- Mild Chronic Sleep Loss and Overlong Sleep: Untangling Thresholds From Reverse CausationNinety minutes of delayed bedtime. Seventy-eight point four minutes of actual sleep lost. One pound gained in six weeks.
- Engineered Enzyme Reverses Glycation Damage Once Thought IrreversibleArticle — "Engineered Enzyme Reverses Glycation Damage Once Thought Irreversible": Article — "Engineered Enzyme Reverses Glycation Damage Once Thought Irreversible": More than 70% of the carboxymethyl-lysine locked into …
Threads we are following
- Whether any institution will commit the $50–100 million needed for a definitive rapamycin lifespan-and-healthspan human trial
- Whether the TAME trial, if funded and run, will confirm or overturn these null randomized findings in non-diabetics
- Whether a randomized trial can confirm the observed 90-119 minute plateau as causal, rather than merely associated
- Whether gene-by-gene dissection of the 78 MR sleep genes can finally separate direct cardiac effects from true sleep-driven risk
- Whether CMLase can penetrate and reduce CML in intact living tissue rather than thin ex vivo sections
One issue a week. Free.
sift. reads hundreds of sources so you don't have to, and sends one issue you can actually finish. No daily noise. Unsubscribe anytime.